A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of GB001 in Patients With Chronic Rhinosinusitis With or Without Nasal Polyps
Latest Information Update: 24 Aug 2021
At a glance
- Drugs GB 001 (Primary)
- Indications Rhinosinusitis
- Focus Proof of concept; Therapeutic Use
- Acronyms TITAN
- Sponsors Gossamer Bio
Most Recent Events
- 13 Oct 2020 According to a Gossamer Bio media release, the company will host a conference call and live audio webcast to discuss the results from this trial.
- 13 Oct 2020 According to a Gossamer Bio media release, the company do not plan to continue further development of GB001 in chronic rhinosinusitis.
- 13 Oct 2020 Primary endpoint (Sino-Nasal Outcome Test-22 (SNOT-22)) has not been met, according to a Gossamer Bio media release.